共 181 条
[1]
Mottet N(2021)EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 79 243-262
[2]
van den Bergh RCN(2018)Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials J Clin Oncol 36 572-580
[3]
Briers E(2018)Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer Ann Oncol 29 2200-2207
[4]
Van den Broeck T(2014)Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 J Natl Cancer Inst 106 dju013-1659
[5]
Cumberbatch MG(2016)Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer J Clin Oncol 34 1652-176
[6]
De Santis M(2016)Predictors of time to metastasis in castration-resistant prostate cancer Urology 96 171-3381
[7]
Heller G(2021)Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel Cancers (Basel) 13 773-1918
[8]
McCormack R(2022)Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort J Cancer Res Clin Oncol 149 3371-1461
[9]
Kheoh T(2022)Baseline modified Glasgow prognostic score [mGPS] predicts radiologic response and overall survival in metastatic hormone-sensitive prostate cancer treated with docetaxel chemotherapy Anticancer Res 42 1911-216
[10]
Molina A(2022)Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors Prostate 82 1456-2185